Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis

Detalhes bibliográficos
Autor(a) principal: Araujo, Kelly Carolina Frauzino
Data de Publicação: 2014
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFG
dARK ID: ark:/38995/0013000005394
Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/7432
Resumo: The "Microbial Models of Mammalian Metabolism" represents an alternative to use of animals on metabolism studies. Introduced in the 70s this model, also called biotranformation, has several advantages for their application as low cost, reduction of animals for experimentation and and higher number and range of metabolites produced. 1-(4-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethanone (LQFM030) and 4-((1-(4-chlorophenyl)-1H-pyrazol-4-il)methyl)piperazin-1-ethyl carboxylate (LQFM018) compounds were synthesized by molecular simplification of a series of compounds with chronic myeloid leukemia antiproliferative activity already described, the Nutlins prototypes. This study aims to produce a probable human metabolites of LQFM 030 and LQFM 018 by microbial biotranformation with filamentous fungi. To do so, analytical methodologies were developed by thin layer chromatography and high performance liquid chromatography in order to monitor metabolites production. After perform a screening of tem microorganisms Mortierella isabellina NRRL 1757 strain was selected to obtain metabolites on a larger scale. Incubations were carried out with 100 mL of glucose culture medium in each flask . At the end of incubation (96 h) extraction and purification of possible metabolites was performed . In an independent assay with LQFM 030, ketoconazole (10, 20 and 30 mg) was added to inhibit P450 cytochrome . In another test 1 mL of ethanol was added every 24 hours to induce cytochrome totaling 96 hours of incubation. To evaluate the best time to finalize incubation , an experiment was conducted in 168 hours with different concentrations of the substrate, 0.25 mg / mL and 50 mg / mL. A possible role of CYP 3A was evidenced by the inhibition caused by ketoconazole addition, that can inhibit the formation of N-oxide metabolite in LQFM 030 biotransformation. Ethanol addition does not induce LQFM 030-N-oxide production, but was able to induce other metabolites formation. The best time to end LQFM 030 incubation was defined as 168 hours and 0.25 mg/mL concentration.
id UFG-2_c1a172016a969cbc9a0a15cf6976000b
oai_identifier_str oai:repositorio.bc.ufg.br:tede/7432
network_acronym_str UFG-2
network_name_str Repositório Institucional da UFG
repository_id_str
spelling Oliveira, Valeria dehttp://lattes.cnpq.br/6300240031300604Oliveira, Valéria deVaz, Boniek GontijoSantos, Pierre Alexandre dosMenegatti, Ricardohttp://lattes.cnpq.br/4275744776508451Araujo, Kelly Carolina Frauzino2017-06-08T13:21:15Z2014-02-28ARAUJO, K. C. F. Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis. 2014. 110 f. Dissertação (Mestrado em Ciências Farmacêuticas) - Universidade Federal de Goiás, Goiânia, 2014.http://repositorio.bc.ufg.br/tede/handle/tede/7432ark:/38995/0013000005394The "Microbial Models of Mammalian Metabolism" represents an alternative to use of animals on metabolism studies. Introduced in the 70s this model, also called biotranformation, has several advantages for their application as low cost, reduction of animals for experimentation and and higher number and range of metabolites produced. 1-(4-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethanone (LQFM030) and 4-((1-(4-chlorophenyl)-1H-pyrazol-4-il)methyl)piperazin-1-ethyl carboxylate (LQFM018) compounds were synthesized by molecular simplification of a series of compounds with chronic myeloid leukemia antiproliferative activity already described, the Nutlins prototypes. This study aims to produce a probable human metabolites of LQFM 030 and LQFM 018 by microbial biotranformation with filamentous fungi. To do so, analytical methodologies were developed by thin layer chromatography and high performance liquid chromatography in order to monitor metabolites production. After perform a screening of tem microorganisms Mortierella isabellina NRRL 1757 strain was selected to obtain metabolites on a larger scale. Incubations were carried out with 100 mL of glucose culture medium in each flask . At the end of incubation (96 h) extraction and purification of possible metabolites was performed . In an independent assay with LQFM 030, ketoconazole (10, 20 and 30 mg) was added to inhibit P450 cytochrome . In another test 1 mL of ethanol was added every 24 hours to induce cytochrome totaling 96 hours of incubation. To evaluate the best time to finalize incubation , an experiment was conducted in 168 hours with different concentrations of the substrate, 0.25 mg / mL and 50 mg / mL. A possible role of CYP 3A was evidenced by the inhibition caused by ketoconazole addition, that can inhibit the formation of N-oxide metabolite in LQFM 030 biotransformation. Ethanol addition does not induce LQFM 030-N-oxide production, but was able to induce other metabolites formation. The best time to end LQFM 030 incubation was defined as 168 hours and 0.25 mg/mL concentration.O “Modelo Microbiano do Metabolismo Animal”, pode representar uma alternativa ao uso de animais nos estudos de metabolismo de novos candidatos a fármacos. Introduzido nos anos 70, este modelo, também denominado de biotransformação, apresenta várias vantagens para a sua aplicação como o baixo custo, a redução da utilização de animais de experimentação e maior quantidade e variedade de metabólitos produzidos. Os compostos 1-(4-((1-(4-clorofenil)-1H-pirazol-4-il)metil)piperazin-1-il)etanona (LQFM 030) e 4-((1-(4-clorofenil)-1H-pirazol-4-il)metil)piperazin-1-carboxilato de etila (LQFM 018) foram sintetizados a partir da simplificação molecular de uma série de compostos com atividade antiproliferativa frente à leucemia mielóide crônica já descrita, os protótipos Nutlins. O presente estudo objetivou a produção de prováveis metabólitos humanos do LQFM 030 e LQFM 018 através de biotransformação microbiana com fungos filamentosos. Para isso, foram desenvolvidas metodologias analíticas por cromatografia em camada delgada e cromatografia líquida de alta eficiência, a fim de se monitorar a produção dos metabólitos. Após seleção dentre dez microrganismos a cepa Mortierella isabellina NRRL 1757 foi escolhida para obtenção de metabólitos em maior escala. A incubação foi realizada com 100 mL de meio de cultura de glicose, em cada Erlenmeyer. Ao término da incubação (96 horas) foi realizada a extração e purificação dos possíveis metabólitos. Em um ensaio independente foi adicionado cetoconazol (10, 20 e 30 mg) ao meio contendo LQFM 030 com o objetivo de inibir o citocromo P450. Em outra etapa foi adicionado 1 mL de etanol a cada 24 horas para induzir o citocromo, totalizando 96 horas de incubação. Para avaliar a melhor cinética reacional, um experimento foi conduzido em 168 horas, com diferentes concentrações do substrato, 0,25 mg/mL e 50 mg/mL. A biotransformação do LQFM 030 e do LQFM 018 produziu seus respectivos N-óxidos, caracterizados por RMN 1H e 13C e EM. Uma provável participação da CYP 3A foi evidenciada através da inibição causada pela adição de cetoconazol capaz de inibir a formação do metabólito N-óxido na biotransformação do LQFM 030. A adição de etanol não induziu a produção do LQFM 030-N-óxido, contudo foi capaz de induzir a formação de outros metabólitos. O melhor tempo para término da incubação do LQFM 030 foi definido como 168 hrs e 0,25 mg/mL de concentração.Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2017-06-08T13:21:01Z No. of bitstreams: 2 Dissertação - Kelly Carolina Frauzino Araujo - 2014.pdf: 2783382 bytes, checksum: f8ddacd33ce41be9f223a9570381c87b (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-06-08T13:21:15Z (GMT) No. of bitstreams: 2 Dissertação - Kelly Carolina Frauzino Araujo - 2014.pdf: 2783382 bytes, checksum: f8ddacd33ce41be9f223a9570381c87b (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2017-06-08T13:21:15Z (GMT). No. of bitstreams: 2 Dissertação - Kelly Carolina Frauzino Araujo - 2014.pdf: 2783382 bytes, checksum: f8ddacd33ce41be9f223a9570381c87b (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2014-02-28Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESapplication/pdfporUniversidade Federal de GoiásPrograma de Pós-graduação em Ciências Farmacêuticas (FF)UFGBrasilFaculdade Farmácia - FF (RG)http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessBiotranformaçãoMortierella isabellinaLQFM 030LQFM 018N-oxidaçãoBiotranformationMortierella isabellinaLQFM 030LQFM 018N-oxidationFARMACIA::ANALISE E CONTROLE E MEDICAMENTOSBiotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóisIn vitro biotransformation of novel N-phenylpyrazole antitumor drug prototypeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesis824936988196152412600600600600601028116152420937562160250746569323362075167498588264571reponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGLICENSElicense.txtlicense.txttext/plain; charset=utf-82165http://repositorio.bc.ufg.br/tede/bitstreams/5dcab194-fdc5-401e-a8a8-c23969f55fda/downloadbd3efa91386c1718a7f26a329fdcb468MD51ORIGINALDissertação - Kelly Carolina Frauzino Araujo - 2014.pdfDissertação - Kelly Carolina Frauzino Araujo - 2014.pdfapplication/pdf2783382http://repositorio.bc.ufg.br/tede/bitstreams/0a927475-ef41-4705-8210-40a8e8ec8c4d/downloadf8ddacd33ce41be9f223a9570381c87bMD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://repositorio.bc.ufg.br/tede/bitstreams/598d660f-e381-4813-b23b-398d541aceda/download4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/99504c0c-84ec-449b-bf1c-86138b77ceb5/downloadd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/1414f0b3-8733-49f2-bef3-0500a4d9b123/downloadd41d8cd98f00b204e9800998ecf8427eMD54tede/74322017-06-08 10:21:15.641http://creativecommons.org/licenses/by-nc-nd/4.0/Acesso Abertoopen.accessoai:repositorio.bc.ufg.br:tede/7432http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2017-06-08T13:21:15Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)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
dc.title.eng.fl_str_mv Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
dc.title.alternative.eng.fl_str_mv In vitro biotransformation of novel N-phenylpyrazole antitumor drug prototype
title Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
spellingShingle Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
Araujo, Kelly Carolina Frauzino
Biotranformação
Mortierella isabellina
LQFM 030
LQFM 018
N-oxidação
Biotranformation
Mortierella isabellina
LQFM 030
LQFM 018
N-oxidation
FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS
title_short Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
title_full Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
title_fullStr Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
title_full_unstemmed Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
title_sort Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis
author Araujo, Kelly Carolina Frauzino
author_facet Araujo, Kelly Carolina Frauzino
author_role author
dc.contributor.advisor1.fl_str_mv Oliveira, Valeria de
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/6300240031300604
dc.contributor.referee1.fl_str_mv Oliveira, Valéria de
dc.contributor.referee2.fl_str_mv Vaz, Boniek Gontijo
dc.contributor.referee3.fl_str_mv Santos, Pierre Alexandre dos
dc.contributor.referee4.fl_str_mv Menegatti, Ricardo
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/4275744776508451
dc.contributor.author.fl_str_mv Araujo, Kelly Carolina Frauzino
contributor_str_mv Oliveira, Valeria de
Oliveira, Valéria de
Vaz, Boniek Gontijo
Santos, Pierre Alexandre dos
Menegatti, Ricardo
dc.subject.por.fl_str_mv Biotranformação
Mortierella isabellina
LQFM 030
LQFM 018
N-oxidação
topic Biotranformação
Mortierella isabellina
LQFM 030
LQFM 018
N-oxidação
Biotranformation
Mortierella isabellina
LQFM 030
LQFM 018
N-oxidation
FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS
dc.subject.eng.fl_str_mv Biotranformation
Mortierella isabellina
LQFM 030
LQFM 018
N-oxidation
dc.subject.cnpq.fl_str_mv FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS
description The "Microbial Models of Mammalian Metabolism" represents an alternative to use of animals on metabolism studies. Introduced in the 70s this model, also called biotranformation, has several advantages for their application as low cost, reduction of animals for experimentation and and higher number and range of metabolites produced. 1-(4-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethanone (LQFM030) and 4-((1-(4-chlorophenyl)-1H-pyrazol-4-il)methyl)piperazin-1-ethyl carboxylate (LQFM018) compounds were synthesized by molecular simplification of a series of compounds with chronic myeloid leukemia antiproliferative activity already described, the Nutlins prototypes. This study aims to produce a probable human metabolites of LQFM 030 and LQFM 018 by microbial biotranformation with filamentous fungi. To do so, analytical methodologies were developed by thin layer chromatography and high performance liquid chromatography in order to monitor metabolites production. After perform a screening of tem microorganisms Mortierella isabellina NRRL 1757 strain was selected to obtain metabolites on a larger scale. Incubations were carried out with 100 mL of glucose culture medium in each flask . At the end of incubation (96 h) extraction and purification of possible metabolites was performed . In an independent assay with LQFM 030, ketoconazole (10, 20 and 30 mg) was added to inhibit P450 cytochrome . In another test 1 mL of ethanol was added every 24 hours to induce cytochrome totaling 96 hours of incubation. To evaluate the best time to finalize incubation , an experiment was conducted in 168 hours with different concentrations of the substrate, 0.25 mg / mL and 50 mg / mL. A possible role of CYP 3A was evidenced by the inhibition caused by ketoconazole addition, that can inhibit the formation of N-oxide metabolite in LQFM 030 biotransformation. Ethanol addition does not induce LQFM 030-N-oxide production, but was able to induce other metabolites formation. The best time to end LQFM 030 incubation was defined as 168 hours and 0.25 mg/mL concentration.
publishDate 2014
dc.date.issued.fl_str_mv 2014-02-28
dc.date.accessioned.fl_str_mv 2017-06-08T13:21:15Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv ARAUJO, K. C. F. Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis. 2014. 110 f. Dissertação (Mestrado em Ciências Farmacêuticas) - Universidade Federal de Goiás, Goiânia, 2014.
dc.identifier.uri.fl_str_mv http://repositorio.bc.ufg.br/tede/handle/tede/7432
dc.identifier.dark.fl_str_mv ark:/38995/0013000005394
identifier_str_mv ARAUJO, K. C. F. Biotransformação in vitro de novos candidatos a protótipos de fármacos antitumorais N-fenilpirazóis. 2014. 110 f. Dissertação (Mestrado em Ciências Farmacêuticas) - Universidade Federal de Goiás, Goiânia, 2014.
ark:/38995/0013000005394
url http://repositorio.bc.ufg.br/tede/handle/tede/7432
dc.language.iso.fl_str_mv por
language por
dc.relation.program.fl_str_mv 824936988196152412
dc.relation.confidence.fl_str_mv 600
600
600
600
dc.relation.department.fl_str_mv 6010281161524209375
dc.relation.cnpq.fl_str_mv 6216025074656932336
dc.relation.sponsorship.fl_str_mv 2075167498588264571
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Goiás
dc.publisher.program.fl_str_mv Programa de Pós-graduação em Ciências Farmacêuticas (FF)
dc.publisher.initials.fl_str_mv UFG
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Faculdade Farmácia - FF (RG)
publisher.none.fl_str_mv Universidade Federal de Goiás
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFG
instname:Universidade Federal de Goiás (UFG)
instacron:UFG
instname_str Universidade Federal de Goiás (UFG)
instacron_str UFG
institution UFG
reponame_str Repositório Institucional da UFG
collection Repositório Institucional da UFG
bitstream.url.fl_str_mv http://repositorio.bc.ufg.br/tede/bitstreams/5dcab194-fdc5-401e-a8a8-c23969f55fda/download
http://repositorio.bc.ufg.br/tede/bitstreams/0a927475-ef41-4705-8210-40a8e8ec8c4d/download
http://repositorio.bc.ufg.br/tede/bitstreams/598d660f-e381-4813-b23b-398d541aceda/download
http://repositorio.bc.ufg.br/tede/bitstreams/99504c0c-84ec-449b-bf1c-86138b77ceb5/download
http://repositorio.bc.ufg.br/tede/bitstreams/1414f0b3-8733-49f2-bef3-0500a4d9b123/download
bitstream.checksum.fl_str_mv bd3efa91386c1718a7f26a329fdcb468
f8ddacd33ce41be9f223a9570381c87b
4afdbb8c545fd630ea7db775da747b2f
d41d8cd98f00b204e9800998ecf8427e
d41d8cd98f00b204e9800998ecf8427e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)
repository.mail.fl_str_mv tasesdissertacoes.bc@ufg.br
_version_ 1815172563903447040